Pennsylvania's Supreme Court was set to hear arguments on drug pricing in two cases. Drugmakers were accused of reporting incorrectly the average wholesale price for treatments reimbursed by Medicaid. Numerous drugmakers "are defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct," Johnson & Johnson said in its quarterly Securities and Exchange Commission report.

Related Summaries